A multi-center, randomized, controlled Phase 2b trial of GH001 in patients with Treatment-Resistant Depression (TRD)
Latest Information Update: 13 Dec 2021
At a glance
- Drugs 5 Methoxy N N Dimethyltryptamine (Primary)
- Indications Depression
- Focus Therapeutic Use
- Sponsors GH Research
- 06 Dec 2021 According to a GH Research media release, the company plan to request a pre-IND meeting with the FDA and a Scientific Advice meeting with the EMA in the first quarter of 2022 for this study.
- 27 Sep 2021 New trial record